Abstract: A system and method for performing a femto-fragmentation procedure on tissue in the crystalline lens of an eye requires that a laser beam be directed and focused to a focal point in the crystalline lens of the eye. The focal point is then guided, relative to an axis defined by the eye, to create a segment cluster by causing Laser Induced Optical Breakdown (LIOB) of tissue in the crystalline lens. The resultant segment cluster includes a plurality of contiguous, elongated segments in the crystalline lens that are individually tapered from an anterior end-area to a posterior end-area. Specifically, this is done to facilitate the removal of individual segments from the segment cluster in the crystalline lens.

Abstract: Method for minimizing the sorption of tear lipids on frequent replacement, or extended-wear, contact lenses, the method comprising (a) contacting the contact lens selected from the group consisting of senofilcon A, lotrafilcon A, lotrafilcon B, and comfilcon A B with a lens care solution for a period of at least three hours to minimize the accumulation of tear lipids on the contact lens. The lens care solution comprises 0.5 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl) ammonium chloride; citrate, citric acid or a mixture thereof; and 0.005 wt. % to 0.05 wt. % hyaluronic acid. The method also includes (b) inserting the soaked contact lens into one's eye, and (c) repeating steps (a) and (b).

Abstract: A combination of an irrigation sleeve 20 and a phacoemulsification needle 22. The irrigation sleeve 20 has a proximal end 32 and a distal end 30, the proximal end for attachment to a surgical handpiece. The phacoemulsification needle 22 has a proximal end 26, a distal end 24, and a lumen 38 spanning a length of the needle 22 from the proximal end 26 to the distal end 24. The needle proximal end 26 is for connection to the surgical handpiece, and the needle 22 has structure 44 proximate the needle distal end 24 for retaining the sleeve distal end 30 near the needle distal end 24.

Abstract: An intraocular lens (IOL) injector assembly comprising an injector body having a shuttle reception opening defined at least in part by a first sidewall and a second sidewall, and a shuttle comprising a first wing including a first portion of a shuttle lumen wall and a second wing including a second portion of a shuttle lumen wall. The first wing and the second wing are coupled together by a hinge. When in a closed state, the first portion of the shuttle lumen wall and the second portion of the shuttle lumen wall define at least a portion of an operative shuttle lumen. The shuttle and sidewalls are configured such that the first wing and the second wing interfere with the first sidewall and the second sidewall, respectively, as the shuttle passes through the shuttle reception opening, such that the closed state of the shuttle is attained.

Abstract: An ophthalmic laser illuminator 10 includes multiple laser devices 12-16. There are at least three different wavelengths of light emitted by the multiple laser devices 12-16 and each wavelength of light emitted by each laser device is outside of wavelengths blocked by a safety filter used for surgical treatment lasers 52. A controller 18 controls the multiple laser devices 12-16. A graphical user interface 32 is operably attached to the controller 18 for allowing a user to select a plurality of light parameters for a light beam exiting the illuminator 10.

Abstract: A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.

Abstract: A system and method for performing a femto-fragmentation procedure on tissue in the crystalline lens of an eye requires that a laser beam be directed and focused to a focal point in the crystalline lens of the eye. The focal point is then guided, relative to an axis defined by the eye, to create a segment cluster by causing Laser Induced Optical Breakdown (LIOB) of tissue in the crystalline lens. The resultant segment cluster includes a plurality of contiguous, elongated segments in the crystalline lens that are individually tapered from an anterior end-area to a posterior end-area. Specifically, this is done to facilitate the removal of individual segments from the segment cluster in the crystalline lens.

Abstract: A packaging system for the storage of an ionic, hydrogel contact lens employs an aqueous packaging solution including a phosphorylcholine polymer. Preferably, the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 8 and is heat sterilized.

Abstract: An ophthalmic surgical device (10) includes a housing (12) having a distal end (14) and a proximal end (16). A cannula (18) is attached to the housing distal end (14) and has a distal tip (20) with at least one port (22) in communication with a lumen (19) extending through the cannula (18) and in communication with an aspiration path (24) in the housing (12). A vibration source (26) is held within the housing (12) for vibrating the distal tip (20) for assisting in vitreous and other tissue removal. An aspiration source (152) connected to the aspiration path (24) for applying a negative pressure to the lumen (19) and the at least one port (22) for removing fluids and the vitreous and other tissue from the eye. The vibration source (26) and the aspiration source (152) together create a periodic bi-directional flow of tissue through the port (22) without creating cavitation externally of the distal tip (20).

Abstract: A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises a polysaccharide, a source of hydrogen peroxide, and an anti-oxidant. The formulation can further comprise a chelating agent and/or an ophthalmically active agent for treating or controlling a disease or disorder of the eye. The formulation may be used to treat, clean, disinfect, store, wet, or rewet contact lenses.

Abstract: An accommodating intraocular lens (AIOL) comprising an optic, and at least one haptic plate coupled to the optic by at least one connector, the connector being less rigid than the haptic plate, the at least one haptic plate surrounding the optic, and the optic and haptic plate having a combined surface area between 70 mm2 and 100 mm2. The at least one haptic plate may form a continuous 360-degree boundary around the optic. The at least one haptic plate has a width in a radial dimension of 1.0-3.5 mm across its entire angular extent.

Abstract: Provided herein is a polymerized product formed of a polymerized monomer mixture comprising intentionally added water and at least one hydrophilic monomer wherein the monomer mix does not contain any silicon containing materials. The polymerized monomer mixture of the invention herein is useful in many biomaterial applications. Especially preferred is the use of the biomaterial as a hydrogel contact lens.

Abstract: A new synthetic method of forming free radical polymerizable end terminal functionalized poloxamers and poloxamines in commercial scale batches which uses a binary system of inhibitors to eliminate the formation of high molecular weight impurities. It has also been surprisingly discovered that the inorganic impurities formed during the commercial scale synthetic process are removed by the use of resin materials.

Abstract: Biomedical devices such as contact lenses formed from a polymerization product of a mixture comprising (a) a multi-armed macromonomer comprising multiple side chains attached to a nucleus, wherein each side chain comprises a thio carbonyl thio fragment of the same or different reversible addition fragmentation chain transfer (“RAFT”) agent; and (b) one or more biomedical device-forming monomers are disclosed.

Abstract: A preloaded intraocular lens injection device includes a retainer for releasably holding an IOL in an unstressed state. The retainer and IOL are removably attached to an injector body and are sealed in the same package for delivery to a surgeon. In an alternate embodiment, the retainer and IOL are coupled together and sealed in one package and the injector body is sealed in a separate package with the surgeon attaching the retainer to the injector body at the time of surgery. To deliver the IOL through the injector body, the retainer is removed from the injector body causing the IOL to release from the retainer and become located in an unstressed state in the injector body. A compressor is moved to the closed position to compress the IOL, the injector tip is inserted through a small incision in an eye and a plunger is advanced to push the IOL through and out the injector body tip and into an eye.

Abstract: A stable ophthalmic pharmaceutical composition for relief, treatment, control, alleviation, or prevention of a pathological ocular condition of the eye comprises: (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, such as a salt, when added to said first polymer; (b) a second polymer that is different from the first polymer and can modify the viscosity of the first polymer; and (c) an oil. In some embodiments, the composition further comprises a non-ionic surfactant. The composition can form a stable oil-in-water emulsion on storage, but separate into an oil phase and a water phase when applied in the eye. The emulsion can comprises an ophthalmic active pharmaceutical ingredient dissolved in the oil or water phase. The emulsion can provide enhanced stability to said active pharmaceutical ingredient.

Abstract: A poly(nitrogen/amine) derivative of a natural wax of formula I, and ophthalmic compositions and contact lens care solutions that contain the poly(nitrogen/amine) derivative of a natural wax of formula I. The invention is also directed to a method of treating a patient with dry eyes, the method comprising instructing a patient to administer one or more eye drops of the ophthalmic composition that includes a poly(nitrogen/amine) derivative of a natural wax of formula I.

Abstract: An optical polymeric material that can substantially block the transmission of ultraviolet light as well as selected portion of violet light. The polymeric material will include monomeric units of one or more lens monomers, and monomeric units of a monomer of formula (I).

Abstract: Method for minimizing the sorption of tear lipids on frequent replacement, or extended-wear, contact lenses, the method comprising (a) contacting the contact lens selected from the group consisting of senofilcon A, lotrafilcon A, lotrafilcon B, and comfilcon A B with a lens care solution for a period of at least three hours to minimize the accumulation of tear lipids on the contact lens. The lens care solution comprises 0.5 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl) ammonium chloride; citrate, citric acid or a mixture thereof; and 0.005 wt. % to 0.05 wt. % hyaluronic acid. The method also includes (b) inserting the soaked contact lens into one's eye, and (c) repeating steps (a) and (b).

Abstract: A thin IOL capable of insertion through a small incision into the capsular bag of an eye includes haptics having free ends configured to absorb compressive forces resulting from shrinkage of the capsular bag in the weeks following surgery.